{"id":89304,"date":"2023-02-21T15:33:00","date_gmt":"2023-02-21T14:33:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=89304"},"modified":"2023-02-21T11:40:16","modified_gmt":"2023-02-21T10:40:16","slug":"this-is-how-munich-biotech-startups-fight-cancer","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/89304\/this-is-how-munich-biotech-startups-fight-cancer\/","title":{"rendered":"How Munich biotech startups are fighting cancer"},"content":{"rendered":"
\n
\"Tubules\"<\/a>
Tubules<\/strong><\/a> develops antibody-drug conjugates (ADCs) designed to attack tumors. These compounds enable the targeted delivery of substances to the tissue affected by a disease. In the case of cancer, this enables, for example, the targeted delivery of chemotherapeutic agents to cancer cells without releasing large amounts of toxic substances into healthy tissue. Founded in 2019 as a spin-off of the Leibniz Research Institute Berlin (FMP) and Ludwig Maximilian University (LMU), the company focuses on stabilizing these ADCs to expand their potential applications. In May 2022, Tubulis raised an additional \u20ac60 million in its Series B round, bringing its total funding to approximately \u20ac72 million. (Image: Carolin Bleese)<\/figcaption><\/figure>\n\n\n\n\n\n\n\n
\"Medical<\/a>
The startup, founded in 2015 by Pascal Schweizer, Martin Hossann and Lars Lindner, Thermosome<\/strong><\/a> is developing a new method for delivering drugs precisely to their intended location in the body. The drug delivery platform technology is based on temperature-sensitive nanocarriers, known as thermosomes. Using a special device, Thermosome slightly heats a tumor compared to the surrounding tissue, so that the intravenously administered drugs only release their active ingredients there. This protects healthy tissue. Compared to conventional drug administration, this should achieve up to 15 times higher local drug concentrations in the diseased tissue. Thermosome's investors include High-Tech Gr\u00fcnderfonds and Bayern Kapital, which most recently injected \u20ac1.9 million into the startup in April 2016.<\/figcaption><\/figure>\n\n\n\n\n\n\n\n
\"Catalym\"<\/a>
In immunotherapies, the body's own immune system is directed against the cancer. This treatment method is considered a particularly pioneering approach. A major challenge is to combine a highly effective immune response against cancer cells with minimal side effects. The Munich-based startup Catalym<\/strong><\/a> is developing new active ingredients for this purpose. The focus is on the drug candidate Visugromab. This is designed to neutralize a specific protein that tumors use to protect themselves from the body's own immune system. This should make the cancer cells accessible to the immune system again, thus strengthening the immune system. With this idea, which stems from research at the University of W\u00fcrzburg, the startup has already won over numerous investors. Most recently, Catalym closed its \u20ac50 million Series C in November of last year. The Munich-based company's total financing is now around \u20ac100 million. (Image: kjpargeter \/ Freepik)<\/figcaption><\/figure>\n\n\n\n\n\n\n\n
\"Plectonic\"<\/a>
The company, founded in early 2022, is still relatively new on the startup scene Plectonic Biotech<\/strong><\/a>Founders Klaus Wagenbauer, Jonas Funke, Benjamin Kick, and Hendrik Dietz have developed an "on\/off switch" for antibody immunotherapies that connects immune cells with tumor cells. The construct, measuring just a few nanometers in size, can dock onto cells on two sides. On one side, the researchers place antibodies against tumor cells, which it uses to identify and bind to tumor cells. This essentially flips a switch that activates other, previously hidden antibodies on the opposite side. These antibodies are recognized by the body's own immune cells, which are then recruited to fight the cancer cells. This should make cancer immunotherapies more targeted and with fewer side effects possible. Last December, the TUM spin-off received its first funding in the form of a Sprind grant. (Image: Sprind)<\/figcaption><\/figure>\n\n\n\n\n\n\n\n
\"Adrian<\/a>
Eisbach Organic<\/strong><\/a> focuses on certain types of cancer in which defective cell division mechanisms lead to constant changes in the tumor genome. This makes these types of cancer particularly difficult to combat. The startup is now attacking the internal mechanisms of cancer cells by interfering with their processes using specific molecules. This ultimately blocks the tumor's disease-relevant functions. The startup, founded by Adrian Schomburg (pictured) and Andreas Ladurner, is also developing a SARS-CoV-19 drug that uses similar mechanisms. For this, the startup received funding of over \u20ac8 million from the Federal Ministry of Education and Research in 2021, as well as a further \u20ac6.7 million from the Bavarian State Government. (Image: Eisbach Bio)<\/figcaption><\/figure>\n<\/div>","protected":false},"excerpt":{"rendered":"

Munich is one of Germany's leading biotech hubs. Research is being conducted here on a wide variety of drugs and therapies, including cancer treatments. We'll introduce you to five startups in more detail.<\/p>","protected":false},"author":33,"featured_media":47419,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5638,1],"tags":[371,4129,4344,2068,4740,1468,4001],"acf":[],"yoast_head":"\nSo bek\u00e4mpfen M\u00fcnchner Biotech-Startups den Krebs - Munich Startup<\/title>\n<meta name=\"description\" content=\"M\u00fcnchen ist einer der f\u00fchrenden Biotech-Standorte Deutschlands. Wir stellen Euch f\u00fcnf Startups vor, die an an Medikamenten gegen Krebs forschen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/89304\/this-is-how-munich-biotech-startups-fight-cancer\/\" \/>\n<link rel=\"next\" href=\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"So bek\u00e4mpfen M\u00fcnchner Biotech-Startups den Krebs - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"M\u00fcnchen ist einer der f\u00fchrenden Biotech-Standorte Deutschlands. Wir stellen Euch f\u00fcnf Startups vor, die an an Medikamenten gegen Krebs forschen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/89304\/this-is-how-munich-biotech-startups-fight-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T14:33:00+00:00\" \/>\n<meta name=\"author\" content=\"Maximilian Feigl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maximilian Feigl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/\",\"url\":\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/\",\"name\":\"So bek\u00e4mpfen M\u00fcnchner Biotech-Startups den Krebs - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg\",\"datePublished\":\"2023-02-21T14:33:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\"},\"description\":\"M\u00fcnchen ist einer der f\u00fchrenden Biotech-Standorte Deutschlands. Wir stellen Euch f\u00fcnf Startups vor, die an an Medikamenten gegen Krebs forschen.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Deutscher Biotechnologie-Report 2019 Biotech\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\",\"name\":\"Maximilian Feigl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"caption\":\"Maximilian Feigl\"},\"description\":\"Maximilian Feigl berichtet seit 2020 \u00fcber das M\u00fcnchner Startup \u00d6kosystem. Dabei haben es dem studierten Politikwissenschaftler vor allem Deeptech-Themen angetan.\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How Munich biotech startups are fighting cancer - Munich Startup","description":"Munich is one of Germany's leading biotech hubs. We introduce you to five startups researching cancer drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/89304\/this-is-how-munich-biotech-startups-fight-cancer\/","next":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/2\/","og_locale":"en_US","og_type":"article","og_title":"So bek\u00e4mpfen M\u00fcnchner Biotech-Startups den Krebs - Munich Startup","og_description":"M\u00fcnchen ist einer der f\u00fchrenden Biotech-Standorte Deutschlands. Wir stellen Euch f\u00fcnf Startups vor, die an an Medikamenten gegen Krebs forschen.","og_url":"https:\/\/cms.munich-startup.net\/en\/89304\/this-is-how-munich-biotech-startups-fight-cancer\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2023-02-21T14:33:00+00:00","author":"Maximilian Feigl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Maximilian Feigl","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/","url":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/","name":"How Munich biotech startups are fighting cancer - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg","datePublished":"2023-02-21T14:33:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509"},"description":"Munich is one of Germany's leading biotech hubs. We introduce you to five startups researching cancer drugs.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/89304\/so-bekaempfen-muenchner-biotech-startups-den-krebs\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg","width":1280,"height":853,"caption":"Deutscher Biotechnologie-Report 2019 Biotech"},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509","name":"Maximilian Feigl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","caption":"Maximilian Feigl"},"description":"Maximilian Feigl has been reporting on the Munich startup ecosystem since 2020. The political scientist is particularly interested in deeptech topics.","url":"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/"}]},"og_image":[{"width":1280,"height":853,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2019\/04\/analysis-2030265_1280.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1684314026:25","_edit_last":"24","_yoast_wpseo_focuskw":"Krebs","_yoast_wpseo_metadesc":"M\u00fcnchen ist einer der f\u00fchrenden Biotech-Standorte Deutschlands. Wir stellen Euch f\u00fcnf Startups vor, die an an Medikamenten gegen Krebs forschen.","_yoast_wpseo_linkdex":"69","_thumbnail_id":"47419","wbounce_status":"default","_yoast_wpseo_primary_category":"5638","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"30","ms_image_format":"hide","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"1","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"4","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/89304"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=89304"}],"version-history":[{"count":4,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/89304\/revisions"}],"predecessor-version":[{"id":89317,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/89304\/revisions\/89317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/47419"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=89304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=89304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=89304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}